ScripUS/Swiss biotech GlycoEra AG announced a $130m series B financing on 27 May that it says will enable it to advance its first protein-degradation drug candidate through Phase II proof of concept as pre
ScripMerck KGaA is pursuing a Phase III program for its novel toll-like receptor 7/8 inhibitor enpatoran in patients with cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE), despite
In VivoIt is a well-known fact that artificial intelligence is changing how drugs are discovered, but how does that reshape the talent profiles that biopharmaceutical companies seek. As the pharmaceutical in
ScripJohnson & Johnson’s Imaavy (nipocalimab) was approved by the US Food and Drug Administration for generalized myasthenia gravis (gMG), but the approval is the first of many the company hopes to sec